Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 33
-1.06%-0.07%+60.76%+68.61% 6.83TCr
+1.30%+7.41%+14.79%+92.69% 6.03TCr
+0.39%+0.30%+20.04%+98.33% 5.59TCr
-0.95%+11.17%+22.21%+110.93% 4.84TCr
-0.23%+4.07%+25.63%+40.08% 4.53TCr
-6.40%-9.51%+181.99%+816.79% 4.18TCr
+1.97%+3.50%+25.78%+50.98% 3.45TCr
-0.56%-0.48%+85.57%+65.40% 3.38TCr
+1.05%+9.77%-37.66%+408.42% 2.62TCr
Average -0.45%+1.46%+44.35%+194.69% 5TCr
Weighted average by Cap. -0.53%+1.44%+45.34%+173.07%
Logo ARYx Therapeutics, Inc.
ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.
Employees
56
  1. Stock Market
  2. Stocks
  3. ARYX Stock